Skip to main content
logo
Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
4.900
+0.360 (7.93%)
At close: Nov 28, 2025, 1:00 PM EST
4.960
+0.060 (1.22%)
After-hours: Nov 28, 2025, 4:18 PM EST

Vistagen Therapeutics Revenue

Vistagen Therapeutics had revenue of $258.00K in the quarter ending September 30, 2025, with 40.98% growth. This brings the company's revenue in the last twelve months to $721.00K, down -17.69% year-over-year. In the fiscal year ending March 31, 2025, Vistagen Therapeutics had annual revenue of $486.00K, down -54.32%.

Revenue (ttm)
$721.00K
Revenue Growth
-17.69%
P/S Ratio
220.83
Revenue / Employee
$12,649
Employees
57
Market Cap
193.53M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Mar 31, 2025486.00K-578.00K-54.32%
Mar 31, 20241.06M1.29M-
Mar 31, 2023-227.00K-1.34M-
Mar 31, 20221.11M19.40K1.78%
Mar 31, 20211.09M--
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro
Mar 31, 2018 Pro Pro Pro
Mar 31, 2017 Pro Pro Pro
Mar 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group435.16B
Johnson & Johnson92.15B
Merck & Co.64.24B
AbbVie59.64B
Eli Lilly and Company59.42B
AstraZeneca58.13B
Novartis AG56.37B
Novo Nordisk49.58B
Revenue Rankings

VTGN News

More News